. Author manuscript; available in PMC: 2015 May 1.

Published in final edited form as: Clin Gastroenterol Hepatol. 2013 Jul 18;12(5):728–737. doi: 10.1016/j.cgh.2013.06.024

Table 4.

Three drug trials +/− RBV

Drug and Trial name	RBV	Patients (genotype 1¹)	Time (wks)	SVR12/ # patients²	(%) SVR		Reference
Drug and Trial name	RBV	Patients (genotype 1¹)	Time (wks)	SVR12/ # patients²	SVR12	SVR24	Reference
ABT 450/r (PI) ABT 267 (NS5A) ABT 333 (NNI) AVIATOR.	Naïve						⁴⁹Kowdley et al. 2013
	+	80	8	71/80	89%	88%
	+	79	12	78/79	99%	96%
	0	79	12	71/79	90%	87%
	+ No ABT267	41	12	35/41	85%	83%
	+ No ABT333	79	12	72/79	91%	89%
	+	80	24	74/80	93%	90%
	Prior Null responders
	+	45	12	42/45	93%	93%
	+ No ABT333	45	12	39/44	89%	89%
	+	43	24	23/24	98%	95%
Drug and Trial name	RBV	Patients/genotype/experience	Time (wks)	SVR/#pts	SVR		Reference
DCV (NS5A) Asunaprevir (PI) BMS-791325 (NNI)	0	16 /1 /naïve 75mg BMS 791325	24	15/16	94% SVR24		⁵⁰Everson et al. 2013
		16 /1 / naïve 75 mg BMS-791325	12	15/16	94% SVR36
		16/ 1 /naïve 150 mg BMS-791325	24	15/16	94% SVR4
		18/1 /naïve 150 mg BMS-791325	12	16/18	8 9% SVR12

Overall, 66% patients were genotype 1a and within groups, 1a and 1b well-mixed.

Patients dosed with drug.